** Massachusetts-based drug developer Neuphoria Therapeutics NEUP.O rises 3.31% to $4.65 in morning trade
** Co, which develops treatments for brain and mental health disorders, says it is due to receive $15 million milestone payment from Merck MRK.N
** The payment is triggered by the start of a mid-stage study for the treatment of Merck's Alzheimer's disease dementia
** The study is estimated to complete on July 20, 2027
** The study is to test if the experimental drug, MK-1167, given along with another therapy that affects memory, which can improve symptoms of Alzheimer's disease dementia such as memory and mental activity
** NEUP is eligible to receive up to $450 million in additional milestone payments if certain developments are achieved
** In the last 12 months, the stock down 70%
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。